Multi-Target Stool DNA Test

Oral anticoagulant or antiplatelet medication use had no substantial effect on the accuracy of multitarget stool DNA testing for colorectal cancer, according to a study published in Gastro Hep Advances.

The FDA approved Exact Sciences’ Cologuard Plus multitarget stool DNA test to screen adults aged 45 years or older at average risk for colorectal cancer, according to a company press release.

Researchers estimated that nearly 60 million individuals aged 45 to 85 years are at average-risk for colorectal cancer and eligible for screening in the U.S., according to cross-sectional study data in JAMA Network Open.

VANCOUVER, British Columbia — A next-generation, multitarget stool DNA test detected colorectal cancer with 94% sensitivity and 91% specificity, outperforming fecal immunochemical testing, according to late-breaking data here.

Next-generation Cologuard exhibited improved colorectal cancer specificity and sensitivity compared with results of the FDA registrational trial that led to approval of the noninvasive screening test, its manufacturer reported.

CHICAGO — Adding a dedicated patient navigator improved fecal immunochemical testing completion and return rates and resulted in significant savings to the health care system, according to data presented at Digestive Disease Week.

March is Colorectal Cancer Awareness Month; in the latest installment of our diversity, equity and inclusion video series with ASGE, Pegah Hosseini-Carroll, MD, proposed strategies for mitigating disparities in CRC screening.

The U.S. Multi-Society Task Force on Colorectal Cancer updated its screening recommendations.